{"prompt": "['Trelagliptin-4002', 'Page 66 of 66', 'Version 2.0', 'July 5,10', '16.0 REFERENCES', '1.', 'Treatment Guide for Diabetes 2016-2017. Edited by Japan Diabetes Society. BUNKODO', 'Corp. 2016', '2.', 'Izumi K, Noda M. In order to reduce the interruption of diabetes treatment. Diabetes Frontier.', '2014;25:709-718.', '3.', 'Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance.', 'Diabetes Care. 1997;20:1512-1517.', '4.', 'Yamazaki M, Higo N, Kaneko T, et.al. SGLT2 Inhibitors As the Trigger for Diabetes Care:', 'Reconfirmed Importance of Behavior Modification After Drug Administration. J.Japan', 'Dab.Soc.2015;58:745-752.', '5.', 'Ishii H. Development and psychometric validation of the Diabetes Therapy-Related QOL', '(DTR-QOL) questionnaire. J Med Econ. 2012;15:556-563.', '6.', 'Bradley C: Diabetes treatment satisfaction questionnaire (DTSQ). In: Handbook of', 'psychology and diabetes (ed. by Bradley C.). Harwood Academic Pubi., Chur, 1994', '7.', 'Ishii H, Bradley C, Riazi A, et al. The Japanese Version of the Diabetes Treatment', 'Satisfaction Questionnaire (DTSQ): translation and clinical evaluation. Journal of Clinical', 'and Experimental Medicine. 2000;192:809-14. (A Japanese Journal published in Japanese)', '8.', 'Sadamoto K, Takamori H, Sadamoto T, et al. Impact of push-through-packages with', 'electronic devices for accurate drug taking. Journal of Scientific and Innovative Research.', '2014;3:288-294.', '9.', 'Report of the Working Group on Conflict of Interest (Ministry of Education, Culture, Sports,', 'Science and Technology dated November 1, 2002)', '10.', 'Guidelines for determining the conflict of interest polity for clinical research (Review group', 'for ethical aspects of clinical study and conflict of interest, March 2006)', '11. Guidelines on the Management of COI in Health and Labor Sciences Research (No. 0331001,', 'science, issued on March 31, 2008, and approved by the Chief of the Health Sciences', 'Division)', '12. Guidelines for management of COI in medical research (COI Committee of Japan', 'Association of Medical Sciences, February 2011)', '13. Common guidelines for conflict of interest (COI) in clinical research (Japanese Society of', 'Internal Medicine, Japan Society of Hepatology, Japanese Circulation Society, Japan', 'Endocrine Society, Japan Diabetes Society, Japanese Respiratory Society, Japanese Society', 'of Hematology, Japanese Society of Allergology, Japanese Association for Infectious', 'Diseases, Japan Geriatrics Society, Aug 2011)', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 1 of 66', 'Version 1.0', 'November 2, 2016', 'PROTOCOL', 'Study of the QOL evaluation of TRElagliptiN in patient with type 2 DiabeteS mellitus', '(TRENDS)', 'Sponsor', 'Takeda Pharmaceutical Company Limited', '12-10 Nihonbashi 2-chome, Chuo-ku, Tokyo', 'Protocol number', 'Trelagliptin-4002', 'Version number/Revision number', 'Version 1.0', 'Study drug', 'Trelagliptin', 'Creation date', 'November 2, 2016', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 2 of 66', 'Version 1.0', 'November 2, 2016', 'CONFIDENTIAL PROPERTY', 'This document is a confidential communication of Takeda. Acceptance of this document constitutes', 'agreement by the potential recipient that no information contained herein will be published or', 'disclosed without written authorization from Takeda except to the extent necessary to obtain', 'informed consent from those study subjects to whom the drug may be administered. Furthermore,', 'the information is only intended for review and compliance by the recipient, his or her staff, and', 'applicable institutional review committee and regulatory agencies to enable conduction of the study.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 3 of 66', 'Version 1.0', 'November 2, 2016', '1.0', 'STUDY ADMINISTRATIVE INFORMATION AND CLINICAL STUDY', 'PRINCIPLES', '1.1', 'Clinical study principles', 'This study will be conducted with the highest respect for the individual participants in accordance', 'with the requirements of this clinical study protocol and also in accordance with the following:', 'The ethical principles that have their origin in the Declaration of Helsinki.', 'Ethical Guideline for Clinical Research (the Ministry of Education, Culture, Sports, Science and', 'Technology and the Ministry of Health, Labour and Welfare, December 22, 2014).', 'Good Clinical Practice: Consolidated Guideline (ICH: International Conference on', 'Harmonization of Technical Requirement for Registration on Pharmaceuticals for Human Use.', 'E6)', 'All applicable laws and regulations, including, without limitation, data privacy laws and conflict', 'of interest guidelines.', '1.2', 'Clinical study implementation system', 'This study will be conducted in accordance with the requirements of this clinical study protocol', 'designed and prepared by the sponsor and also in accordance with the following. Other study', 'administrative structures are shown in the separate documents.', 'Sponsor', 'Japan Medical Affairs, Japan Pharma Business Unit, Takeda Pharmaceutical Company Limited', 'The sponsor shall be responsible for matters related to planning/preparation,', 'implementation/operation, and results/reporting in this clinical study. Methods of supervision of the', 'contractor entrusted with the services related to this clinical study will be described in the procedure', 'to be prepared separately.', 'Expenses* required for the operation of this clinical study will be paid by the sponsor.', '*', ': Based on the \"Consignment Service Contract,\" expenses incurred for the services of Office of', 'Clinical Study, monitoring, registration/allocation center, and statistical processing shall be paid', 'to the contractor entrusted with services related to this clinical study. Expenses agreed by the', 'study site shall be paid to the site based on the \"Research Expense Standard.\"', 'CONFIDENTIAL']", "completion": ""}